Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nanumi Han

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Oncoimmunology|August 3, 2023
A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by OxaliplatinNanumi Han, Haruka Wada, Takuto Kobayashi, et al.
Journal of Leukocyte Biology|August 2, 2018
Interleukin-34, a comprehensive reviewMuhammad Baghdadi, Yui Umeyama, Naoki Hama, et al.
STAR Protocols|April 26, 2021
An optimized protocol for patient-derived xenograft in humanized mice to evaluate the role of IL-34 in immunotherapeutic resistanceNanumi Han, Hye Yoon Jang, Naoki Hama, et al.
Inflammation and Regeneration|March 9, 2018
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanomaNanumi Han, Muhammad Baghdadi, Kozo Ishikawa, et al.
Inflammation and Regeneration|October 19, 2020
Bromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cellsNanumi Han, Delnur Anwar, Naoki Hama, et al.
Journal of Gynecologic Oncology|January 5, 2023
Interleukin-34 cancels anti-tumor immunity by PARP inhibitorTakayoshi Nakamura, Nabeel Kajihara, Naoki Hama, et al.
Iscience|November 18, 2020
Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint BlockadeNaoki Hama, Takuto Kobayashi, Nanumi Han, et al.
Immunological Medicine|November 26, 2019
Prognostic value of IL-34 in colorectal cancer patientsTakuto Kobayashi, Muhammad Baghdadi, Nanumi Han, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2024
Glutamine is critical for the maintenance of type 1 conventional dendritic cells in normal tissue and the tumor microenvironmentGraham P Lobel, Nanumi Han, William A Molina Arocho, et al.
Iscience|January 14, 2022
Erratum: Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint BlockadeNaoki Hama, Takuto Kobayashi, Nanumi Han, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Oncoimmunology|August 3, 2023
A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by OxaliplatinNanumi Han, Haruka Wada, Takuto Kobayashi, et al.
Journal of Leukocyte Biology|August 2, 2018
Interleukin-34, a comprehensive reviewMuhammad Baghdadi, Yui Umeyama, Naoki Hama, et al.
STAR Protocols|April 26, 2021
An optimized protocol for patient-derived xenograft in humanized mice to evaluate the role of IL-34 in immunotherapeutic resistanceNanumi Han, Hye Yoon Jang, Naoki Hama, et al.
Inflammation and Regeneration|March 9, 2018
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanomaNanumi Han, Muhammad Baghdadi, Kozo Ishikawa, et al.
Inflammation and Regeneration|October 19, 2020
Bromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cellsNanumi Han, Delnur Anwar, Naoki Hama, et al.
Journal of Gynecologic Oncology|January 5, 2023
Interleukin-34 cancels anti-tumor immunity by PARP inhibitorTakayoshi Nakamura, Nabeel Kajihara, Naoki Hama, et al.
Iscience|November 18, 2020
Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint BlockadeNaoki Hama, Takuto Kobayashi, Nanumi Han, et al.
Immunological Medicine|November 26, 2019
Prognostic value of IL-34 in colorectal cancer patientsTakuto Kobayashi, Muhammad Baghdadi, Nanumi Han, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2024
Glutamine is critical for the maintenance of type 1 conventional dendritic cells in normal tissue and the tumor microenvironmentGraham P Lobel, Nanumi Han, William A Molina Arocho, et al.
Iscience|January 14, 2022
Erratum: Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint BlockadeNaoki Hama, Takuto Kobayashi, Nanumi Han, et al.
Pageof 2